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Abstract: Both genetic and epigenetic changes contribute to development of human cancer. Oncogenomics has primarily 
focused on understanding the genetic basis of neoplasia, with less emphasis being placed on the role of epigenetics in tu-
mourigenesis. Genomic alterations in cancer vary between the different types and stages, tissues and individuals. Moreo-
ver, genomic change ranges from single nucleotide mutations to gross chromosomal aneuploidy; which may or may not 
be associated with underlying genomic instability. Collectively, genomic alterations result in widespread deregulation of 
gene expression profiles and the disruption of signalling networks that control proliferation and cellular functions. In addi-
tion to changes in DNA and chromosomes, it has become evident that oncogenomic processes can be profoundly influ-
enced by epigenetic mechanisms. DNA methylation is one of the key epigenetic factors involved in regulation of gene ex-
pression and genomic stability, and is biologically necessary for the maintenance of many cellular functions. While there 
has been considerable progress in understanding the impact of genetic and epigenetic mechanisms in tumourigenesis, 
there has been little consideration of the importance of the interplay between these two processes. In this review we sum-
marize current understanding of the role of genetic and epigenetic alterations in human cancer. In addition we consider the 
associated interactions of genetic and epigenetic processes in tumour onset and progression. Furthermore, we provide a 
model of tumourigenesis that addresses the combined impact of both epigenetic and genetic alterations in cancer cells.  
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INTRODUCTION 
  It is well-established that an important part of the cancer 
etiology lies in stepwise accumulation of genetic changes 
[1]. DNA mutation leads to aberrant RNA and protein, with 
widespread deregulation of transcription during oncogenesis. 
The phenotypic outcomes of genetic changes in cancer have 
led to a general classification of cancer genes as either tu-
mour suppressors, which are involved in inhibition of cell 
growth and survival, or oncogenes which promote these ef-
fects [2]. Genetic change not only plays a significant role in 
tumourigenesis, but it is also associated with inter- and intra-
tumour heterogeneity [3]. A major challenge facing cancer 
researchers today is to understand how genomic change can 
lead to the acquisition of such cellular heterogeneity [4]. 
New models of oncogenomic progression must consider the 
combined effect of epigenetic and genetic change and con-
comitant causation of tumour heterogeneity. 
  The term epigenetics was first introduced by a British 
embryologist and geneticist Conrad Hal Waddington in 
1940, and was used to describe the study of the causal analy-
sis of development [5]. Today, epigenetics refers to the study 
of heritable changes in gene expression without the change 
in gene sequence. These heritable changes are propagated as  
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covalent chemical changes to the cytosine bases and are re-
ferred to as DNA methylation. Regulation of chromatin 
compaction and DNA accessibility through spatial and tem-
poral distribution of these chemical signals ensures appropri-
ate genomic responses across different developmental stages 
and tissue types. In contrast, the deregulation of epigenetic 
patterns leads to induction and propagation of disease states 
[6]. The maintenance of these epigenetic signals through cell 
divisions ensures appropriate regulation of gene activation 
and repression. DNA methylation uniquely fits the descrip-
tion of an epigenetic mechanism as in addition to playing a 
role in regulation of gene expression, it is heritable with a 
clearly defined mechanism of propagation through cell divi-
sion [7]. In addition to DNA methylation, other mechanisms 
including histone tail modifications, ATP-dependent chro-
matin remodelling or non-coding RNAs play an important 
role in gene regulation and chromatin compaction, but their 
heritability is less clear.  
  The hallmark of cancer is the deregulation of gene ex-
pression profiles and disruption of molecular networks [2]. 
Mutation and genomic instability provide tumours with suf-
ficient diversity, so that cells with adaptive and proliferative 
advantage can evolve in a Darwinian manner. However, it 
has become evident that epigenetic factors, particularly heri-
table changes in DNA methylation, may confer an additional 
selective advantage to tumours. While there is some under-
standing of how such genetic and epigenetic changes may 
influence the gene expression, and thereby tumour evolution, 
it is less clear how these mechanisms may influence each Cause and Consequences of Genetic and Epigenetic Alterations  Current Genomics, 2008, Vol. 9, No. 6    395 
other, and how these cumulative changes may co-evolve and 
influence gene expression during tumourigenesis. This re-
view provides an overview of the literature including some 
recent developments that give insights into the important 
question of co-evolution of epigenetic changes in tumouri-
genesis and cancer progression.  
  In the first section we review our current understanding 
of different types of genetic changes in cancer, and provide 
some specific examples of each. The second section focuses 
on DNA methylation where we review both normal func-
tions of DNA methylation, disruptions of DNA methylation 
in human disease, and changes in DNA methylation in hu-
man cancer. The final sections focus on literature evidence 
of combined epigenetic and genetic changes in oncogenes 
and tumour suppressors, and addresses how DNA methyla-
tion may influence genomic stability. We provide an 
epi/genetic model of tumour evolution and conclude by dis-
cussion of its implications in cancer biology.  
GENETIC CHANGES IN CANCER 
  Cancer develops as a result of cellular acquisition of spe-
cific growth advantages through the stepwise accumulation 
of genetic and chromosomal changes. Since several genetic 
alterations are generally required for a cancer to fully de-
velop, the malignant phenotype is determined in part by the 
combined disruption of tumour suppressor genes and activa-
tion of oncogenes. Cancer genomes can be highly unstable 
and typically exhibit extensive genomic changes, ranging 
from intragenic mutations, to gross gains and losses of 
chromosomal material (aneuploidy) [8-10]. In the following 
section we will review our current understanding of genetic 
changes underlying the deregulation of tumour suppressor 
genes and oncogenes while providing some common exam-
ples of each (Table 1), and discuss the correlation of such 
changes to overall genomic instability. 
Tumour Suppressor Inactivation 
  Genetic mutations, deletions and allelic loss of tumour 
suppressor genes during tumourigenesis lead to an aberrant 
or absent RNA transcript and concomitant loss of the func-
tion of the translated protein. 
Mutations 
  Intragenic mutations that inactivate genes with roles in 
maintenance of genomic integrity and various tumour sup-
pressor pathways are common in cancer. These genetic al-
terations directly or indirectly suppress the normal function 
of tumour suppressor genes resulting in disruption of cell 
cycle control and shifting the balance in favor of cell prolif-
eration [11, 12]. One of the most commonly mutated tumour 
suppressor genes in human cancer is P53. It is localized to 
chromosome 17p13 and its inactivation is central to the 
pathogenesis of many tumours including breast cancer, brain 
tumours, and sarcomas [13, 14]. Inactivation of P53 by mu-
tations is the most frequent and earliest detectable genetic 
alteration during glioblastoma progression. Glioblastoma is 
the most common brain tumour where the P53 mutation pat-
tern is characterized by frequent G:C-->A:T mutations at 
CpG sites which is seen in 60% of the precursor low-grade 
astrocytomas [15]. Inactivation of P53 in osteosarcoma, the 
most common cancer of bone in children, can occur by mu-
tations in the gene itself or by alterations of its regulatory 
genes. Alterations of P53 gene by point mutations is evident 
in 30 % of osteosarcoma tumours [13, 16]. These mutations 
can be detected before or after the development of osteosar-
coma metastasis, an indication that P53 mutations may be an 
early event in this disease [17]. Germ-line mutations of P53 
lead to Li-Fraumeni syndrome and predispose affected pa-
tients to a variety of tumours, particularly sarcomas [18].  
  Another example of the commonly mutated tumour sup-
pressor genes are BRCA1 and BRCA2, which are the only 
known high penetrance genes involved in breast cancer 
susceptibility [19, 20]. Most of the mutations that affect 
these two genes result in protein truncations, which often 
involve small insertions, deletions or nonsense mutations. 
About 10% of breast cancer cases that are due to BRCA1 or 
BRCA2 mutations are considered familial, but the majority 
of breast cancer cases are sporadic. Only a small fraction of 
the remaining risk is attributed to germline mutations in 
other known genes (for example, the P53 tumour suppressor, 
or the PTEN gene) [21].  
  Many other examples of mutations of tumour suppressors 
are evident in cancer and include RB1, APC, PTEN, P21 and 
others. Some examples and their major tumour sites are 
listed in (Table 1). 
Deletions and Allelic Loss 
  In addition to mutational inactivation of tumour suppres-
sors which usually involve single nucleotide changes, inacti-
vation of these genes can also be caused by loses of large 
chromosomal regions or entire chromosomes. Examples of 
tumour suppressors that are affected by deletions or allelic 
loss include major regulators of G1 to S transition of cell 
cycle, the retinoblastoma gene (RB) [22] and the INK4 gene 
locus [23]. Children with a germline mutation in one of their 
RB alleles are likely to experience bilateral multifocal reti-
noblastoma [12]. This gene is located on the long arm of 
chromosome 13, a region with loss of heterozygosity (LOH) 
in approximately 60% of osteosarcoma tumours [24, 25]. 
Gross structural rearrangements of the RB gene are present 
in up to 30% of osteosarcoma tumours, and point mutations 
appear to be far less frequent, occurring in less than 10% 
[25, 26]. Heterozygosity for germ line mutations in RB pre-
disposes patients to the hereditary form of retinoblastoma, 
and these patients have a significant increase in the fre-
quency of primary and radiation related osteosarcoma [27]. 
Other studies on sporadic osteosarcoma reported the pres-
ence of RB gene alterations in about 70% of the cases and 
correlated alterations in this gene to late stages of osteosar-
coma development [28]. These alterations include structural 
rearrangements, complete deletions or less frequently point 
mutations. 
  The INK4 locus on chromosome 9p21 codes for 
P16
INK4A, P15
INK4B and P14
ARF genes. While P14
ARF is in-
volved in the P53 pathway, P16
INK4A is a tumour suppressor 
gene that inhibits CDK4, which in a complex with cyclin D1, 
facilitates the transition from G1 to S phase in cell cycle by 
phosphorylating RB. Deletion of INK4 locus was reported in 
10% of osteosarcomas [23]. Loss of P16
INK4A function re-
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mutations [23, 28]. Moreover, chromosome region 12q13 is 
amplified in a subset of osteosarcoma [23]. This region is a 
genomic location for CDK4 (in addition to MDM2) genes. 
Higher levels of CDK4 may lead to RB phosphorylation 
impairing its function in cell cycle control [105]. CDK4 gene 
is amplified in 9% of osteosarcoma tumours [23] making this 
event significant in osteosarcoma pathogenesis as it can im-
pact the RB pathway. 
  Another example of a frequently deleted tumour suppres-
sor is PTEN. This gene is involved in modulation of the 
phosphatidylinositol-3-kinase (PI3K) pathway and is re-
quired for activation of the important regulatory protein 
kinase AKT. The PTEN locus at chromosome 10q24 is sub-
ject to frequent (~40%) genomic deletions in prostate can-
cers [106], with a significant association between PTEN de-
letion and an earlier onset of disease recurrence and a greater 
likelihood of metastatic disease.  
  In contrast to the loss of tumour suppressor genes, the 
process of tumour initiation and progression also requires 
gains or activation of oncogenes. 
Table 1.  Genetic and DNA Methylation Changes in Common Cancer Related Genes 
Cancer-Related Genes  Genetic Change  DNA Methylation  Major Tumour Sites / Types  References 
Tumour Suppressor Genes 
P53  mutations, allelic loss and LOH  hypermethylation  breast, brain, sarcomas including osteosarcoma  [18, 29-32] 
RB  mutations, allelic loss and deletions  hypermethylation  retinoblastoma  [33-42] 
APC  mutations  hypermethylation  colon, thyroid, intestine, stomach  [43-46] 
MSH2 & MLH1  mutations hypermethylation  colon,  uterus  [47-49] 
WT1  allelic loss  hypermethylation  Wilms' tumors  [50-52] 
PTEN  mutations and LOH  hypermethylation  glioma, uterus  [53-55] 
P21 (CDKN1A)  mutations  hypermethylation  squamous cell carcinoma, melanoma  [56, 57] 
INK4A, ARF  deletions  hypermethylation  melanoma, osteosarcoma  [23, 28, 58, 59] 
ATM  mutations  hypermethylation  leukemia, lymphoma, brain  [60-62] 
BRCA1, BRCA2  mutations, LOH, deletions, allelic loss  hypermethylation  breast, ovary  [19, 63-69] 
REQL4  mutations  ?  skin, osteosarcoma  [70, 71] 
Oncogenes 
EWS/FLI-1  translocations  ?  Ewing’s sarcoma  [72, 73] 
BCR/ABL  translocations ?  CML  [74,  75] 
MYC  amplifications  hypomethylation  lung, breast, colorectal, head/neck, osteosarcoma  [76-79] 
RAS and RAS-family  mutations  hypomethylation  lung, colon, pancreas, AML  [80-85] 
CDK4  amplification ?  osteosarcoma  [23] 
FOS  amplifications hypomethylation  osteosarcoma  [86,  87] 
EGFR (ERBB2)  amplifications  hypermethylation  glioblastoma, head/neck, osteosarcoma  [88-91] 
PAX3/FKHR  translocations ?  alveolar,  rhabdomyosarcoma  [92] 
DHFR  amplifications ?  ALL  [93,  94] 
MET  mutant allele duplications  ?  papillary renal carcinoma  [95, 96] 
FGFR1  amplification hypomethylation  rhabdomyosarcoma  [97] 
RET  mutant allele duplications  ?  endocrine neoplasia  [98-100] 
CCND1  amplifications and translocations  ? 
breast, esophageal, hepatocellular, head/neck, 
mantle-cell lymphoma 
[76, 101-103] 
TMPR552/ERG1 or 
TMPR552/ETV1 
translocations ?  prostate  cancer  [104] Cause and Consequences of Genetic and Epigenetic Alterations  Current Genomics, 2008, Vol. 9, No. 6    397 
Oncogene Activation 
  The major types of genetic changes that result in onco-
gene activation are mutations, chromosomal translocations, 
or gene amplifications. Oncogene mutations have a gain of 
function or dominant-acting role in tumourigenesis. 
Mutations 
  When an oncogene is activated by a mutation, the struc-
ture of the encoded protein is changed in a way that enhances 
its transforming activity. An example of commonly mutated 
oncogenes is the RAS oncogene family, which when mu-
tated encode proteins that remain in the active state and con-
tinuously transduce signals by linking tyrosine kinases to 
downstream serine and threonine kinases. These stable sig-
nals induce continuous cell growth. Mutations of k-RAS are 
common in carcinomas of the lung, colon, and pancreas 
[107], whereas mutations of n-RAS occur principally in 
acute myelogenous leukaemia and the myelodysplastic syn-
drome [108]. 
Chromosomal Translocations 
  Oncogenic translocations involve rearrangements of 
chromosomes that result in formation of protein coding 
genes with oncogenic functions or activity under conditions 
in which the wild-type gene is inactive. A classic example of 
oncogene activation by chromosomal translocations in can-
cer is observed in chronic myelogenous leukaemia, which is 
initiated by a reciprocal t(9;22) chromosomal translocation 
that fuses the ABL proto-oncogene to the BCR gene [109, 
110]. The fusion gene encodes an oncogenic BCR/ABL fu-
sion protein with enhanced tyrosine kinase activity. All leu-
kaemic cells carry this chromosomal alteration, which is why 
inhibition of the excessive tyrosine kinase activity of the 
fusion protein induces complete remission in most patients 
[111, 112]. An additional example of oncogene activation by 
chromosomal translocation is the t(11;14) translocation that 
juxtaposes cyclin D1 (CCND1) and immunoglobulin enhan-
cer elements and is characteristic of mantle-cell lymphoma 
[113, 114]. 
Chromosomal translocations can also activate transcription-
factors in cancers. For example, in Ewing’s sarcoma the 
EWS gene is fused with one of a number of genes, leading to 
altered transcriptional activity of the fused proteins [115]. 
The EWS protein is an RNA-binding molecule that, when 
fused to a heterologous DNA binding domain, can greatly 
stimulate gene transcription [104]. Prostate carcinomas carry 
translocations of the TMPR552 gene that fuse with and acti-
vate ERG1 or ETV1. These genes are members of the ETS 
family of transcriptional factors, which can activate or re-
press genes involved in cellular proliferation, differentiation, 
and apoptosis. The fusion of TMPR552 with an ETS-related 
gene creates a fusion protein that increases proliferation and 
inhibits apoptosis of cells in the prostate gland, thereby fa-
cilitating their transformation into cancer cells [116]. 
Genomic Amplifications 
  Oncogene activation by genomic amplification, which 
usually occurs during tumour progression, is seen in the 
members of different oncogene families including MYC, 
CCND, EGFR, and FOS. MYC is amplified in small-cell 
lung cancer, breast cancer, esophageal cancer, cervical can-
cer, ovarian cancer, and head and neck cancer. c-MYC gene 
is also amplified in a small subset of osteosarcomas [78, 
117] and its product was found to be overexpressed more 
frequently in relapsed and metastatic disease [118]. CCND1 
amplification occurs in breast, esophageal, hepatocellular, 
and head and neck cancer. EGFR (also called HER2/neu and 
ERBB2) is amplified in glioblastoma and head and neck 
cancer. Amplification of EGFR in breast cancer correlates 
with a poor prognosis [119]. Amplification is also seen in the 
dihydrofolate reductase gene (DHFR) in methotrexate-
resistant acute lymphoblastic leukaemia [93, 94]. Amplifica-
tion of DHFR is accompanied by cytogenetic alterations that 
mirror amplification of oncogenes [120, 121]. The amplified 
DNA segment usually involves several hundred kilobases 
and can contain many genes. 
  The c-FOS oncogene is overexpressed in a number of 
tumours including osteosarcoma breast carcinoma, cervical 
cancer, ovarian cancer and lung cancer [122]. In osteosar-
coma c-FOS is amplified leading to its over expression [118] 
however in the other tumour types, the role of amplification 
in the gene overexpression is unresolved. It was isolated as 
the cellular homologue of the v-FOS gene found in the os-
teosarcoma inducing FBR- and FBJ-murine sarcoma viruses 
[123]. c-Fos oncogene is a transcription factor on chromo-
some 6q21 and its activation induces transformation in cul-
tured cells [124]. Moreover, when the viral homologue v-
FOS was injected into mice, osteosarcoma formation was 
enhanced [125]. Expression of c-FOS has been shown to be 
highly elevated in 60% of osteosarcoma samples [87]. Ele-
vated expression of c-FOS was correlated with high-grade 
more frequently than with low-grade osteosarcoma [87]. 
Overexpression of c-FOS have been observed more often in 
patients who developed metastases than those who remained 
metastases free [118]. 
  While activation of specific oncogenes and disruptions of 
individual tumour suppressors alter the tumour phenotype in 
a specific manner, cumulative effects of such changes may 
be more apparent in tumours with higher levels of genomic 
instability. Most cancers have an abnormal chromosomal 
content characterized by changes in chromosomal structure 
and number. Chromosomal aberrations are generally more 
numerous in malignant tumours than in benign ones, and the 
karyotypic complexity and cellular heterogeneity observed is 
often associated with poor prognosis. 
Genomic Instability 
  Genomic instability refers to a series of chromosomal 
changes occurring at an accelerated rate in cell populations 
derived from the same ancestral precursor [3]. It is a general 
term to describe the overall processes that increase the rate 
of mutation, thus enabling cells to develop new and aggres-
sive phenotypes to adapt to the changing selection pressures 
[3]. Genomic instability is generally classified into two ma-
jor types: microsatellite instability (MIN), and chromosomal 
instability (CIN) [126]. MIN involves simple DNA base 
changes that occur due to defects in the DNA repair proc-
esses including base excision repair, mismatch repair and 
nucleotide excision repair [127, 128]. CIN, on the other 
hand, is characterized by grossly abnormal karyotypes, fea-398    Current Genomics, 2008, Vol. 9, No. 6  Sadikovic et al. 
turing both structural and numerical chromosome abnormali-
ties [129]. MIN and CIN mechanisms are generally found to 
be mutually exclusive and to produce different phenotypes 
[129] although recent findings suggest there may be some 
overlap in these two pathways [130]. 
  Genome-wide and gene-specific epigenetic changes may 
presumably have similar effects on chromosomal structure 
and number in the affected cells. One of the challenges fac-
ing cancer researchers today is to understand how cancer 
cells acquire genomes with such a high degree genomic in-
stability, and to determine in what way the genome and epi-
genome of cancer maybe interacting to facilitate the occur-
rence of such instability. In the coming section we will re-
view some of the basic knowledge of epigenetic processes of 
DNA methylation and its relevance in cancer with special 
focus on the relationship between epigenetic and genetic 
mechanisms in tumours. 
DNA METHYLATION 
  DNA methylation is an epigenetic process involved in 
regulation of many cellular processes including gene expres-
sion, imprinting, X chromosome inactivation, silencing of 
retroviral and transposable DNA elements, and chromatin 
organization. DNA methylation refers to the addition of a 
methyl group to the fifth position of a cytosine. Methylated 
cytosines are present in the DNA of all vertebrates and flow-
ering plants, some fungal, invertebrate and protist taxa, many 
bacterial species, and is common to all large genome eu-
karyotes [131]. In the following sections we will review our 
current knowledge of proteins involved in establishment and 
maintenance of DNA methylation including DNA methyl-
transferases and methyl binding proteins, normal functions 
of DNA methylation, changes in DNA methylation machin-
ery related to human disease, and DNA methylation in hu-
man cancer.  
The DNA Methyltransferases (DNMTs) 
  Cytosine methylation is mediated by proteins called 
DNA (cytosine-5) methyltransferases. It has been more   
than 30 years since the prediction of two different classes of 
DNA methyltransferases (DNMTs) [132, 133]: maintenance 
DNMTs that preserve the patterns of DNA methylation dur-
ing cell division by specifically acting on the hemimethy-
lated DNA produced by semiconservative replication, and de 
novo DNMTs that establish methylation patterns on specific 
sequences early in development. Five DNA methyltrans-
ferases whose functions have been characterized have been 
identified including: DNMT1, DNMT2, DNMT3a, DNMT3b, 
and DNMT3L.  
  The first DNA methyltransferase enzyme to be purified 
was DNMT1 [134]. Subsequent experiments showed that 
DNMT1 has an increased rate of methylation on hemimethy-
lated DNA compared to the unmethylated DNA [135]. This 
preference of DNMT1 for hemimethylated DNA caused it to 
be assigned function of maintenance methyltransferase, al-
though it is the only methyltransferase to be purified and 
cloned based on its de novo methylase property. The second 
DNMT to be identified based on its similarity to the bacterial 
type II cytosine-5’ methyltransferase was DNMT2 [136]. 
Although DNMT2 is the most strongly conserved and most 
widely distributed [131], it remains as the most enigmatic 
DNMT because it shows no detectable DNA methyltrans-
ferase activity [137]. Two additional DNA methyltrans-
ferases were identified from the EST databases and due to 
their similarity were named DNMT3a and DNMT3b [136, 
138]. Mouse DNMT3a and DNMT3b were shown to de novo 
methylate DNA in human cells, with each enzyme having 
specific preferences for the different DNA regions [139]. 
The methyltransferase, DNMT3L, is a protein that is ho-
mologous to the other DNMT3s but has no catalytic activity. 
Instead, DNMT3L was shown to assist the de novo methyl-
transferases in establishment of maternal imprinting patterns 
during development [140, 141]. 
The Methyl-Binding Proteins 
  In addition to the DNMTs, proteins which recognize and 
bind to methylated DNA play an important role in chromatin 
regulation. These include methyl-CpG-binding 2 protein 
(MeCP2) and methyl-binding domain proteins (MBD1 
through 5). 
  MeCP2 was the first protein which was found to specifi-
cally bind methylated CpGs [142, 143]. It was also shown 
that MeCP2 can bind chromatin and that it plays a role in 
transcriptional repression of genes with methylated promot-
ers through interactions with mSin3a/HDAC (histone deace-
tylase) chromatin remodelling complexes [144, 145]. Dele-
tion of MeCP2 gene in mice results in embryonic lethality 
[146]. MBD1 through 4 were identified by database screen-
ing using the methyl-binding domain (MBD) of MeCP2 
[147]. MBD1 was found to act as a transcriptional repressor 
in an HDAC-dependant manner, but does not associate with 
MeCP2-related complexes [148]. MBD2 binds methylated 
promoters and represses transcription through HDAC-related 
complexes, similarly to MeCP2 [149, 150]. MBD3 is a com-
ponent of a Mi-2/NuRD transcriptional co-repressor complex 
[151, 152]. MBD4 is a glycosylase which removes mis-
matched thymine or uracil opposite CpG dinucleotides [153]. 
MBD5 was identified using a yeast-two-hybrid screen using 
p120 catenin and was named Kiaso [154]. It acts as a tran-
scriptional repressor, but unlike MeCP2 and MBD2 which 
bind a single symmetrically methylated CpG, Kiaso requires 
at least a pair of CpGs [155].  
Normal Functions of DNA Methylation 
    The establishment and maintenance of proper DNA 
methylation patterns is essential for growth and develop-
ment, as well as many cellular processes such as imprinting, 
X chromosome inactivation, silencing of retroviral and 
transposable DNA elements, and chromatin organization.  
  DNMT gene targeting experiments have shown the ne-
cessity of these methyltransferases in embryonic develop-
ment. For example, Dnmt1 deficient mice displayed embry-
onic lethal phenotype with reduced size and gross morpho-
logical abnormalities at day 10.5 d.p.c. [156]. Also, mainte-
nance enzyme Dnmt3a  and Dnmt3b double knockouts 
showed a premature lethal phenotype at 4 weeks of age and 
at the late embryonic stages respectively, as well as lack a of 
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  Further evidence that DNA methylation is essential for 
development comes from imprinting studies. Imprinting is a 
process in which a number of developmentally-important 
genes are marked for specific expression from either paternal 
or maternal chromosomes during oocyte and sperm produc-
tion [158]. While differential DNA methylation plays a role 
in this process, disruption of DNA methylation in DNA 
methyltransferase-deficient mice has been shown to result in 
deregulation of expression in a number of imprinted genes 
including H19, insulin-like growth factor 2 (Igf-2), and Igf-2 
receptor (Igf-2r) [159]. 
  An additional important role of DNA methylation relates 
to the X chromosome. First recognized in 1948 by Murray 
Barr, the “Barr body” was later shown to be a product of X-
chromosome inactivation. Inactivation of one of the two cop-
ies of X-chromosomes in mammalian females ensures gene 
dosage compensation to mammalian males, which carry a 
single X-chromosome [160]. DNA methylation is essential 
for appropriate X-inactivation, along with other mechanisms 
including histone modifications [161].  
  In addition to silencing the X-chromosome, most of the 
methylated cytosines in human DNA reside in, and repress, 
transposable and retroviral elements. It was shown that the 
loss of DNA methylation in Dnmt1-/- mice resulted in de-
methylation and transcriptional activation of intracisternal 
type A particle (IAP) retroviruses in developing mouse em-
bryos [162]. Methylation of these sequences which include 
Alu, and short and long interspersed nuclear sequences 
(SINE and LINE), also increases the rate of their mutational 
inactivation  via  cytosine to thymine transitions. As such, 
DNA methylation is thought to have evolved as a mecha-
nism related to containment of these potentially harmful ge-
nomic elements [163]. 
  This broad functionality of DNA methylation in mam-
malian cells validates the need for stringent regulation of this 
process. Aberrant DNA methylation results in disruption of 
genomic and gene specific methylation profiles and ulti-
mately leads to many human diseases. 
DNA Methylation and Human Disease 
  Many human diseases have been linked to aberrant DNA 
methylation or mutations in the DNA methylation machin-
ery. The most common mutation-related diseases are Rett 
syndrome and ICF syndrome, as well as disorders related to 
aberrant imprinting such as Angelman syndrome, Prader-
Willi syndrome, and Beckwith-Wiedemann syndrome.  
  Rett syndrome is caused by a dominant mutation in the 
X-linked methyl-CpG-binding MeCP2 gene [164]. It is 
thought that brain-derived neutrophic factor (BDFN), which 
is a specific target for MeCP2 [165], is one of the genes that 
is deregulated due to the loss of transcriptional repression of 
its target genes via mutant MeCP2. Immunodeficiency, Cen-
tromere instability, and Facial anomalies (ICF) syndrome 
which is caused by mutations in DNMT3b [166], is charac-
terized by centromeric instability of chromosomes 1, 9 and 
16, which is associated with abnormal hypomethylation of 
CpG sites within pericentromeric satellite regions. Expres-
sion profiling of ICF patients identified over 30 genes spe-
cific for lymphocyte signalling that are deregulated in this 
immune system disorder as a result of a DNMT3b mutation 
[167]. The two imprinting disorders Angelman and Prader-
Willi syndrome are associated with the loss or mutation of 
the common imprinting centre at the 15q11-q13 region that 
contains 4 paternally and 2 maternally expressed imprinted 
genes [168]. Angelman syndrome is characterized by the 
loss of maternal contribution of 15q11-q13 or by paternal 
uniparental disomy (UPD) [169], while PWS results from 
deletion of paternal 15q11-q13 or maternal UPD [170]. An 
additional imprinting disorder, Beckwith-Weidemann syn-
drome, can be caused by mutations in the CDKN1C gene, 
alterations in the 11p15 region that result from parental 
UPD, or by deletions resulting in a loss of imprinting in this 
region [168, 171, 172]. 
  There is also emerging evidence of links between aber-
rant DNA methylation and many other human diseases and 
conditions including neurological and cardiovascular disor-
ders, imprinting and paediatric syndromes, reproductive 
problems, and aging [173]. The most compelling evidence of 
DNA methylation disorders and human pathogenesis is evi-
dent in human cancer.  
DNA Methylation and Human Cancer 
  Malignant cells show major disruptions in their DNA 
methylation profiles which manifest as hypermethylation of 
gene promoters, global hypomethylation, and increased rate 
of mutation at methylated CpG dinucleotides. 
  Hypermethylation of CpG islands in gene promoters has 
been the most extensively studied area of research of DNA 
methylation in cancer. In contrast to the rest of the human 
genome, which is largely deprived of CpG dinucleotides, 
approximately half of all human genes promoters are associ-
ated with CpG-enriched regions (0.5-5 kb) called CpG is-
lands [174]. In normal cells, the majority of the CpG islands 
are not methylated, allowing for transcription of their associ-
ated genes. In cancer cells, hypermethylation of these re-
gions results in the loss of gene expression [7]. To date, 
many genes with aberrant promoter hypermethylation have 
been identified in essentially all forms of cancer. Some of 
these susceptible genes include cell cycle regulators (P16
INK4a, 
P15
INK4a, RB, P14
ARF), DNA repair genes (BRCA1, MGMT, 
MLH1), genes associated with apoptosis (DAPK, TMS1), 
hormonal regulation (ER) detoxification (GSTP1), metasta-
sis (E-cadherin, CD-44), angiogenesis (TSP-1, TIMP-3) and 
many others [175, 176]. Although some genes such as p16 
are methylated in many cancers, other genes are methylated 
in specific types of cancer [176]. An example is GSTP1 
which is hypermethylated in over 90% of prostate cancers, 
but is largely unmethylated in acute leukaemia [177, 178].  
  The second form of DNA methylation defect in many 
types of cancer is genomic hypomethylation [179]. It is 
common in both solid tumours such as prostate cancer [180], 
hepatocellular cancer [181], cervical cancer [182], as well as 
in haematologic cancers such as B-cell chronic lymphocytic 
leukaemia [183]. Aberrant hypomethylation has been hy-
pothesized to contribute to cancer progression by activating 
oncogenes such as H-RAS [81], BORIS/CTCFL [184], 
FGFR1 [97], c-MYC [185], or by retrotransposon activation 
[186, 187] or by increasing chromosome instability as in ICF 
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  Finally, DNA methylation is also linked to tumourigene-
sis through mutational gene inactivation. Deamination of a 
methylated cytosine in the CpG dinucleotide causes a cyto-
sine to thymidine transitional mutations in genes such as the 
tumour suppressor P53 and the human LDL receptor [189]. 
Analysis of DNA methylation in the coding regions of 
BRCA1, RB1, and NF1 showed prevalent CpG methylation, 
including those CpGs at mutational hotspots of these genes 
[190-192].  
INTERPLAY OF EPIGENETIC AND GENETIC 
CHANGES IN CANCER 
  While much of our understanding of cancer as a genetic 
or epigenetic disease comes from studies focusing on either 
mechanism specifically, some of the early studies and par-
ticularly many of the new developments in the field are re-
vealing the importance of the interplay of both genetic and 
epigenetic changes in tumours. Genomic imbalance and 
DNA methylation have been shown to disrupt normal gene 
expression and gene dosage, while disruptions of DNA 
methylation profiles may play a role in genomic instability 
especially at repeat-rich sequences. 
  It has been nearly a decade since Knudson’s two-hit hy-
pothesis was expanded to encompass aberrant DNA methy-
lation as an alternative inactivation mechanism for disruption 
of tumour suppressor gene expression [193]. Many studies at 
that time focused on promoter DNA hypermethylation as a 
means of inducing loss of tumour suppressor gene function. 
(Table 1) shows a list of some of the most common tumour 
suppressors that have been identified to date, whose expres-
sion has been shown to be affected by both genetic aberra-
tions as well as promoter DNA hypermethylation. Hyper-
methylation of tumour suppressor genes in cancer has been 
reviewed extensively and reader should refer to the follow-
ing references for more information [6, 7, 194-196]. In addi-
tion to promoter DNA hypermethylation of tumour suppres-
sors, promoter DNA hypomethylation of oncogenes can af-
fect gene expression similarly to a genomic amplification or 
oncogenic translocation.  
  The first identified cancer-related aberrant methylation of 
a gene promoter was hypomethylation of c-Ha-RAS and c-
Ki-RAS oncogenes in primary human carcinomas in 1983 
[81]. Recently, FGFR1 amplification in rhabdomyosarcomas 
was associated with both hypomethylation of its upstream 
CpG island as well as overexpression of this gene and induc-
tion of its downstream targets [97]. c-MYC is another onco-
gene that was shown to be hypomethylated in acute leukae-
mia derived from myelodysplastic syndromes [185]. In a 
recent study it was shown that hypomethylation of the LINE 
1 retrotransposon, as well as amplification of MYC can be 
used to predict tumour stage in prostate cancer [197]. Ge-
nome wide functional approach using Decitabine exposure 
identified oncogenes ELK1, FRAT2, r-RAS, RHOB, and 
RHO6, as gene candidates that are silenced by DNA methy-
lation in normal stomach mucosa but are activated by DNA 
demethylation in a subset of gastric cancers. Authors further 
showed that demethylation of specific CpG sites within the 
first intron of r-RAS causes its activation in more than half 
of gastric cancers [82]. Another study showed drastic hy-
pomethylation and overexpression of Ha-RAS gene pro-
moter in a mouse carcinogenesis model which authors con-
cluded supports the hypothesis that tumour promotion in-
volves instability of the epigenome, providing an environ-
ment where changes in the methylation status of specific 
regions of the genome accumulate progressively and con-
tribute to the clonal expansion of initiated cells that leads to 
tumour formation [80]. Similarly, another group showed 
hypomethylation of Ha-Ras gene promoter in response to a 
high arsenic diet of a mouse carcinogenesis model [83]. En-
vironmental exposure studies have shown that carcinogenic 
chemicals such as arsenic and selenium may cause genomic 
DNA hypomethylation during the process of detoxification 
of these metals [198, 199]. Exposures to benzo(a)pyrene 
carcinogen were shown to induce genome wide DNA and 
repeat-specific hypomethylation, and histone hyperacetyla-
tion in a breast cancer model [200-202]. Therefore, cumula-
tive evidence indicates that much like hypermethylation of 
tumour suppressors, hypomethylation of oncogenes plays a 
critical role in tumour evolution, and that genomic hy-
pomethylation is linked to process of carcinogenesis in gen-
eral. 
  These findings suggest that DNA methylation provides 
an additional “layer” of control of gene expression during 
the process of tumourigenesis. Furthermore, there is now 
increasing evidence that methylation may be more directly 
involved in the process of genomic destabilization and hu-
man cancer. In addition to genomic instability, global DNA 
hypomethylation is evident in many cancers including pros-
tate [180], hepatocellular [181], cervical [182], B-cell 
chronic lymphocytic leukaemia [183], bladder [203] and 
liver cancer [204]. Decreased levels of global DNA methyla-
tion appear to be indicative of increased pathologic grade in 
many malignancies including those of breast, cervix and 
brain [179].  
  The hypomethylation in cancer cells of retrotransposons 
such as LINE elements can cause their transcriptional activa-
tion [205]. Such active transposons can disrupt other genes 
through mutational insertions. For example, an active L1 
LINE element was shown to disrupt the c-MYC and APC 
genes in breast and colon cancer respectively [206]. Recent 
genomic array profiling of DNA methylation in lung cancer 
identified extensive DNA hypomethylation in tumours oc-
curs specifically at repetitive sequences, including short and 
long interspersed nuclear elements and LTR elements, seg-
mental duplications, and subtelomeric regions [207]. Hy-
pomethylation of repeat elements in cancer is particularly 
intriguing given the causative roles such sequences play in 
generation and propagation of genomic instability [208]. 
Another study involving genome-wide characterization of 
hypomethylated sites in human tissues and breast cancer cell 
lines has also identified megabase-sized hypomethylated 
zones that are associated with large genes, fragile sites, evo-
lutionary breakpoints, chromosomal rearrangement break-
points, and tumour suppressor genes [209]. Analysis of DNA 
methylation of genomic DNA repetitive elements (LINE1, 
Alu, Satellite-alpha and Satellite-2) during the progression of 
CML from chronic phase to blast crisis showed that chronic- 
phase CML samples were significantly more hypomethy-
lated for all repetitive sequences compared with normal 
samples and a more profound level of hypomethylation was 
observed among blast crisis samples compared to chronic Cause and Consequences of Genetic and Epigenetic Alterations  Current Genomics, 2008, Vol. 9, No. 6    401 
phase samples [210]. Another group showed a strong corre-
lation between LINE1 hypomethylation and amplification of 
8q chromosome arm in prostate cancer [211]. Genomic gain 
of 1q arm in hepatocellular carcinoma was also shown to be 
significantly correlated to hypomethylation of centromeric 
heterochromatin satellite 2 DNA, at the 1q12 fragile site 
[212]. The major breakpoint cluster region (M-BCR) that is 
involved transformation of CML from the chronic to the 
blastic phase was shown to undergo various levels of hy-
pomethylation related to lymphoid-crisis patients studied in 
blastic phase. Therefore, in addition to reactivation of onco-
gene expression, global DNA hypomethylation plays a role 
in reactivation of repetitive elements and subsequent genome 
destabilization.  
EPI/GENETIC MODEL OF TUMOUR EVOLUTION 
  It has become evident that there is a strong link between 
epigenetic disruptions of DNA methylation and regions of 
genomic instability in human cancer. While early studies 
focused primarily on DNA hypermethylation of tumour sup-
pressors, an increasing body of evidence indicate that hy-
pomethylation of oncogenes represents another epigenetic 
event common in tumourigenesis. In addition to directly af-
fecting gene expression, DNA methylation plays an impor-
tant role in maintenance of genomic stability, particularly by 
repressing repetitive genomic elements, disruption of which 
is closely related to genomic instability and chromosomal 
aberrations. Fig. (1) presents our model of tumour progres-
sion in which underlying genetic and epigenetic changes 
drive tumour evolution by disrupting both normal gene ex-
pression and gene dosage, while concurrently increasing 
genomic instability, and as a result providing selective ad-
vantage to newly formed tumour cells.  
  This model further adds to Jones and Laird model [193] 
which primarily focused on genetic and DNA hypermethyla-
tion-mediated tumour suppressor inactivation, by including 
both hypomethylation of oncogenes and hypomethylation of 
repeat elements as key events in genomic destabilization and 
tumour evolution. Our model suggests that normal gene ex-
pression profiles depend on both genomic content and epige-
netic DNA methylation profiles, which coordinately ensure 
appropriate levels of gene expression in normal cells. Fur-
thermore, normal patterns of genomic DNA methylation play 
a crucial role in repression and condensation of inactive and 
repetitive elements thereby ensuring appropriate chromatin 
conformation in these regions. When such elements are dis-
rupted chromatin changes may lead to instability with conse-
quent chromosomal and expression changes. During the evo-
lution of tumour phenotype disruptions of both genetic and 
epigenetic DNA methylation profiles, such as loss and/or 
hypermethylation of tumour suppressors, gain and/or hy-
pomethylation of oncogenes, as well as increased genomic 
instability related to disruption of genomic and epigenomic 
profiles will have selective advantages in the population of 
tumour cells. This process can drive the evolution of tumour 
cells, and provide selective advantages to cells with most 
favourable gene expression phenotypes, which as we suggest 
will be a result of a dual “layer” control through both genetic 
changes and DNA methylation.  
  In addition to genetic and DNA methylation changes, 
many other factors may play a role in genomic stability and 
regulation of gene expression including chromatin-related 
factors such as histone tail modifications and ATP-
dependent chromatin remodelling complexes, transcriptional 
factor binding, non-coding regulatory RNA molecules, tissue 
microenvironment and others. The unique characteristic of 
both genetic changes and DNA methylation is that they are 
heritable. By definition, heritability is a requirement for the 
concept of tumour evolution. As we understand more about 
many other factors that may influence tumour evolution and 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Acquisition of genetic and epigenetic changes disrupts normal gene expression and provides selective advantage to cancer cells. 402    Current Genomics, 2008, Vol. 9, No. 6  Sadikovic et al. 
the potential heritability of such mechanisms through the cell 
cycle, this model may be augmented to include those 
changes.  
    Another important feature of many solid and haema-
tologic cancers is the remarkable inter- and intra-tumour 
heterogeneity in both genetic changes and DNA methylation 
profiles. Since changes in gene expression and subsequent 
disruption of protein network interactions allow for and are a 
major driving force in tumour evolution, underlying regula-
tory mechanisms of gene expression must play an important 
role. Complimentary and sometimes mutually exclusive ge-
netic and epigenetic roles may provide a dual “layer” of con-
trol of gene expression that neither mechanism alone can 
address independently. Fig. (2) illustrates how dual “layer” 
genetic and DNA methylation changes can provide selective 
advantages with greater plasticity for the tumour evolution, 
whilst simultaneously increasing tumour heterogeneity and 
proliferative/selective advantages for the most adaptive cel-
lular subtypes. 
IMPLICATIONS OF EPI/GENETIC MODEL OF TU-
MOUR EVOLUTION 
  Our ability to identify diagnostic, prognostic, and thera-
peutic genetic changes in majority of tumours has been very 
limited. Focusing solely on genetic changes that may under-
lay changes in gene expression and therefore influence tu-
mour evolution may have biased our predictive capability to 
a single “layer” of at least dual-layered levels of heritable 
control of gene expression. Focusing solely on epigenetic 
changes in DNA methylation may suffer from the same bias. 
Therefore, in order to increase our predictive power in the 
studies of mechanisms underlying heritable changes in gene 
expression profiles and consequently tumour evolution, there 
needs to be an emphasis on the integration of genetic and 
epigenetic information in relation to gene expression 
changes on the genomic level.  
  Biotechnological revolution in the past decade has for the 
first time allowed for genome wide screening of expression 
profiles, genomic changes, and most recently epigenomic 
changes in DNA methylation, allowing for some remarkable 
improvements in our understanding of cancer genotype, epi-
genotype, and gene expression phenotype. With the devel-
opment of biologist-friendly integrative software tools we 
may for the first time be able to increase our predictive pow-
ers for detection of mechanisms responsible for the acquisi-
tion of cancer phenotype and tumour evolution. 
  While genetic changes are permanent and virtually irre-
versible, epigenetic changes in DNA may be reversed. In a 
clinical setting DNA methylation represents a very attractive 
target for the development and implementation of new thera-
peutic approaches. Much effort is spent on identification of 
potential chemotherapeutics that may modulate DNA methy-
lation, and one of them, Decitabine, is currently being used 
in clinic. Many clinical trials are ongoing and epigenetic 
therapy has recently been approved by the United States 
Food and Drug Administration (US FDA) for the use in the 
treatment of myelodysplastic syndrome (MDS) and primary 
cutaneous T-cell lymphoma (CTCL). Identification of epige-
netically-deregulated gene pathways in the context of tu-
mour-specific genetic changes may provide a therapeutic 
target at the gene transcription level, augmenting our efforts 
of targeting the genetic disruptions at the level of protein. 
However, given the non-specific nature of current epigenetic 
drugs that may target and reactivate oncogenes in addition to 
the tumour suppressors, caution and further investigation of 
gene-specific methylation modifying drugs are warranted. 
  In addition to being reversible, epigenetic changes in 
DNA methylation are environmentally responsive in toxico-
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Co-evolution of genetic and epigenetic changes creates tumour heterogeneity, increases replicative potential and drives tumour evo-
lution. Cause and Consequences of Genetic and Epigenetic Alterations  Current Genomics, 2008, Vol. 9, No. 6    403 
logical, nutritional, and psychosocial sense [213]. As such, 
integration of epigenetic information to the genetic profiles 
of cancer may for the first time allow us to gain a more com-
plete understanding of genetic basis and environmental in-
fluences in the etiology of this complex disease. 
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ABBREVIATIONS 
LOH  =   Loss of heterozygosity 
MIN =    Microsatellite  instability 
CIN  =   Chromosomal instability 
DNMT =    DNA  methyltransferase 
MBD =    Methyl-binding  domain 
MECP2  =   Methyl-CpG-binding 2 protein 
HDAC =    Histone  deacetylase 
LINE  =   Long interspersed nuclear element 
SINE  =   Short interspersed nuclear element 
IAP  =   Intracisternal type A particle 
UPD  =   Uniparental disomy  
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